u/titration_marshal

Retitled to match the body. The original promised a comparison the post does not make.

Weekly dosing again, half-life in the same neighbourhood as sema, so a step change takes about a month to reach steady state. Judging a new step at day five is judging noise.

Flairing Results and pinning alongside the noise-vs-plateau explainer post, they pair well together — one's the theory, this is the data backing it.

hold the dose that works, the ladder is not a leaderboard

phase 3 data will change most of what gets said here

Adding the standing caveat — nothing here is approved standalone and research material is not for human use.

This. Ask for the batch record. The ones who send it inside a day have told you more than any review could.

Trial identifiers corrected in the title. SURMOUNT and SURPASS are different programmes.

Correction to my own post above — I said 5mg and I have been on 7.5mg since the spring. Same argument, wrong number.

Which week did the appetite change actually land for you?

week 10 is early to draw any conclusion at all

Yes. Spread across lots is the number that tells you about the process. A single high result tells you about a vial.

Retitled to match the body. The original promised a comparison the post does not make.

Sent a vial to Janoshik because there was nothing on file. 99.0% against a claimed 98.5%. First entry for this compound in my own log.

Minor fix — the half-life is about a week, not about a day. The rest of your point stands.

Where the evidence actually stands, since every thread here assumes a different answer.

Phase 2 reported a large mean body weight change at 48 weeks across a few hundred participants with a slow, protocol-driven escalation. The effect size was striking. The confidence intervals were wide, the population was small, and the duration was under a year.

Phase 3 is running. Until it reports, everything else — including the ranking arguments this board loves — is extrapolation from a small study. That is not a criticism of the compound; it is a description of the evidence.

Why this compound is not simply another agonist, which is how it gets described everywhere else.

Amylin is co-secreted with insulin and signals satiety through its own receptor complexes. It is a different axis from the incretin system, not a parallel version of it. That is why the combination story is interesting: two mechanisms that address appetite differently, rather than more agonism at one receptor.

It is also why the dosing intuitions people bring from the semaglutide and tirzepatide boards do not transfer. Different receptors, different exposure-response, and no published schedule anybody here can reason from.

The endpoint vocabulary, because you cannot read this literature without it.

Resolution of steatohepatitis without worsening of fibrosis and improvement in fibrosis without worsening of steatohepatitis are the two standard composite endpoints, both scored on biopsy by pathologists against a defined system. Liver fat fraction is an imaging surrogate that correlates imperfectly with histology.

A trial can move the surrogate substantially and the histological endpoint modestly. Both results are real; they answer different questions. Anybody quoting a response rate here should say which endpoint it refers to, and most summaries do not.

No training or nutrition prescriptions for other members. Describe what you did.

the ladder exists because the gut needs the time, not because the pharmacy likes paperwork

Agreed that receptor distribution is the key to the side-effect map. It is not a mystery, it is anatomy.

albumin binding is most of the half-life story

research-use-only material is not approved for human use, full stop

The phase 2 readout ran to 48 weeks in a few hundred participants with a slow escalation. Both the size and the duration matter when people quote the headline number.

read the combination arms separately from the monotherapy arms

Agreed, and the combination arms are where the interesting numbers actually live.

Leaving this up. It is a check-in, it has numbers, and it is honest about being one person.

Retitled to match the body. The original promised a comparison the post does not make.

Does the effect persist with continued dosing or does tolerance develop?

Adding the caveat the paper itself makes in its limitations section, which is stronger than anything in this thread.

Sceptical of the extrapolation. Forty-eight weeks does not tell you about seventy-two, and the curve shape is exactly what is unknown.

Removed the conversion table. There is no published equivalence between the two molecules and posting one as fact is exactly the kind of thing that gets copied for years.

The escalation schedule in the trials existed to keep people on the drug. It is a tolerability ramp, and it is why the label reads the way it does.

Compared two scans from different clinics and panicked over a difference that was inside the error margin.

Have the lifts held, dropped, or moved around?

Why this compound is not simply another agonist, which is how it gets described everywhere else.

Amylin is co-secreted with insulin and signals satiety through its own receptor complexes. It is a different axis from the incretin system, not a parallel version of it. That is why the combination story is interesting: two mechanisms that address appetite differently, rather than more agonism at one receptor.

It is also why the dosing intuitions people bring from the semaglutide and tirzepatide boards do not transfer. Different receptors, different exposure-response, and no published schedule anybody here can reason from.

Disagree — that is a weight endpoint from a different programme and you are quoting it in a hepatic context.

Are the missed weeks in there as blanks or dropped entirely?

Phase 2 estimates effect and finds a dose range.

Agreed, and the glucagon arm is exactly why the comparison threads do not work.

protein and resistance training, that is the entire intervention

Flairing this as a check-in rather than a question, since that is what it turned into.

Glucose-dependent insulin secretion is why hypoglycaemia risk is low as monotherapy: the effect scales with glycaemia rather than acting unconditionally.

Removed the conversion table. There is no published equivalence between the two molecules and posting one as fact is exactly the kind of thing that gets copied for years.